Status: Recruiting
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
The trial will be an open label, single arm, phase 2 study to assess the tolerability and efficacy of HLX-1502 in participants with NF1 that are 16 years or older in age with progressive and/or symptomatic PN. This study will also investigate the safety and efficacy of HLX-1502 in a small cohort of 12 to 15 year olds.
Participants needed: 25
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Healx LimitedUpdated: May 19, 2026Locations: 14
Eligibility criteria
All participants must have a diagnosis of NF1 based on the 2021 revised consensu... [+10]
Prior treatment with HLX-1502 for a PN. [+17]